Literature DB >> 25284168

Tacrolimus therapeutic drug monitoring and pediatric renal transplant graft outcomes.

Nicholas Larkins1, Douglas G Matsell.   

Abstract

Predose monitoring of tacrolimus levels is standard practice in the care of pediatric renal transplant patients. This is despite a paucity of data investigating the ideal target range in children, and controversy as to whether tacrolimus levels correlate with renal transplant outcomes. We performed a retrospective cohort analysis of 48 renal transplant patients at a single Canadian pediatric transplant center following the initiation of a tacrolimus-mycophenolate-prednisone-based IS protocol. We analyzed the relationship of graft function, as defined by GFR up to five yr post-transplant, to the preceding mean tacrolimus level. There was no significant correlation between absolute GFR and mean tacrolimus levels (r = 0.206, p = 0.38). However, a higher mean tacrolimus level, particularly ≥10 ng/mL in the first three months after transplantation, was associated with a slower rate of decline in GFR with time (r = 0.608, p = 0.004) and with a less likelihood of developing CKD five yr after transplant. We suggest that the optimal target range for tacrolimus levels may be at the upper end of what is currently practiced and that further research to validate these findings would be useful.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  kidney transplantation; outcome; pediatric; tacrolimus; therapeutic drug monitoring

Mesh:

Substances:

Year:  2014        PMID: 25284168     DOI: 10.1111/petr.12369

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  4 in total

1.  Infection rates in tacrolimus versus cyclosporine-treated pediatric kidney transplant recipients on a rapid discontinuation of prednisone protocol: 1-year analysis.

Authors:  Sarah J Kizilbash; Michelle N Rheault; Ananta Bangdiwala; Arthur Matas; Srinath Chinnakotla; Blanche M Chavers
Journal:  Pediatr Transplant       Date:  2017-03-31

2.  Patterns in Tacrolimus Variability and Association with De Novo Donor-Specific Antibody Formation in Pediatric Kidney Transplant Recipients.

Authors:  Kim H Piburn; Vaka K Sigurjonsdottir; Olafur S Indridason; Lynn Maestretti; Mary Victoria Patton; Anne McGrath; Runolfur Palsson; Amy Gallo; Abanti Chaudhuri; Paul C Grimm
Journal:  Clin J Am Soc Nephrol       Date:  2022-07-26       Impact factor: 10.614

3.  Risk Factors for Subtherapeutic Tacrolimus Levels after Conversion from Continuous Intravenous Infusion to Oral in Children after Allogeneic Hematopoietic Cell Transplantation.

Authors:  Michelle Kolb; Katharine Offer; Zhezhen Jin; Justine Kahn; Monica Bhatia; Andrew L Kung; James H Garvin; Diane George; Prakash Satwani
Journal:  Biol Blood Marrow Transplant       Date:  2016-02-13       Impact factor: 5.742

4.  The potential impact of hematocrit correction on evaluation of tacrolimus target exposure in pediatric kidney transplant patients.

Authors:  Anne M Schijvens; Fransje H S van Hesteren; Elisabeth A M Cornelissen; Charlotte M H H T Bootsma-Robroeks; Roger J M Brüggemann; David M Burger; Saskia N de Wildt; Michiel F Schreuder; Rob Ter Heine
Journal:  Pediatr Nephrol       Date:  2018-10-30       Impact factor: 3.714

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.